SINE compounds, such as selinexor, that are potent XPO1 inhibitors are able to simultaneously target numerous pathways in NHL cells, leading to cytotoxic effects and sensitization to other anti-cancer agents. This evidence concerns the gene XPO1 and non-Hodgkin lymphoma.